NasdaqCM - Delayed Quote USD
Heron Therapeutics, Inc. (HRTX)
1.0700
+0.0100
+(0.94%)
At close: November 22 at 4:00 PM EST
1.0900
+0.02
+(1.87%)
After hours: November 22 at 5:04 PM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Jan 1970) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | -- | 2 | 2 |
| Avg. Estimate | -0.03 | 0 | -0.12 | -0.03 |
| Low Estimate | -0.03 | 0 | -0.14 | -0.05 |
| High Estimate | -0.02 | 0 | -0.1 | 0 |
| Year Ago EPS | -0.07 | -- | -0.8 | -0.12 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Jan 1970) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | -- | 3 | 3 |
| Avg. Estimate | 37.37M | -- | 140.87M | 167.3M |
| Low Estimate | 36.5M | -- | 140M | 162M |
| High Estimate | 38.2M | -- | 141.7M | 175M |
| Year Ago Sales | 34.23M | -- | 127.04M | 140.87M |
| Sales Growth (year/est) | 9.15% | -- | 10.88% | 18.76% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.15 | -0.09 | -0.05 | -0.04 |
| EPS Actual | -0.07 | -0.02 | -0.06 | -0.03 |
| Difference | 0.08 | 0.07 | -0.01 | 0.01 |
| Surprise % | 54.35% | 77.78% | -28.56% | 14.29% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Jan 1970) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.03 | 0 | -0.12 | -0.03 |
| 7 Days Ago | -0.03 | 0 | -0.12 | -0.01 |
| 30 Days Ago | -0.03 | 0 | -0.13 | 0 |
| 60 Days Ago | -0.03 | 0 | -0.13 | 0 |
| 90 Days Ago | -0.03 | 0 | -0.13 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Jan 1970) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 1 | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | HRTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 64.29% | -- | -- | 5.00% |
| Next Qtr. | -- | -- | -- | 12.00% |
| Current Year | 85.00% | -- | -- | 2.10% |
| Next Year | 79.17% | -- | -- | 12.20% |
Upgrades & Downgrades
| Maintains | Needham: Buy to Buy | 11/13/2024 |
| Reiterates | Needham: Buy to Buy | 9/25/2024 |
| Reiterates | Needham: Buy to Buy | 8/7/2024 |
| Initiated | Rodman & Renshaw: Buy | 6/13/2024 |
| Reiterates | Needham: Buy to Buy | 5/16/2024 |
| Reiterates | Needham: Buy to Buy | 5/8/2024 |
Related Tickers
KPTI Karyopharm Therapeutics Inc.
0.8450
+8.67%
ARDX Ardelyx, Inc.
5.31
+3.71%
FGEN FibroGen, Inc.
0.3954
+2.12%
MREO Mereo BioPharma Group plc
3.7200
+1.09%
INZY Inozyme Pharma, Inc.
2.8100
+4.46%
CTMX CytomX Therapeutics, Inc.
0.8900
+2.71%
ATRA Atara Biotherapeutics, Inc.
11.47
+8.11%
ARQT Arcutis Biotherapeutics, Inc.
10.14
-0.98%
HOOK HOOKIPA Pharma Inc.
2.1500
-6.52%
AUTL Autolus Therapeutics plc
2.9400
+3.52%